Upregulation of miR-200a-M inhibits Keap1/Nuclear factor erythroid 2-related factor 2(NRF2) signaling, which ultimately could attenuate hyperglycemia-induced inflammation and endothelial dysfunction (60). The gene discussed is NFE2L2; the disease is endothelial dysfunction.